Lipocine (NASDAQ:LPCN) Upgraded at Wall Street Zen

Lipocine (NASDAQ:LPCN) was upgraded by Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Sunday.

Other equities research analysts also recently issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $15.00 price target (up from $7.00) on shares of Lipocine in a research report on Wednesday, January 21st. Weiss Ratings reissued a “sell (d-)” rating on shares of Lipocine in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Lipocine currently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Lipocine Stock Performance

NASDAQ:LPCN opened at $7.15 on Friday. Lipocine has a 52 week low of $2.52 and a 52 week high of $12.37. The firm has a market cap of $52.20 million, a price-to-earnings ratio of -4.24 and a beta of 0.98. The firm’s 50-day simple moving average is $9.06 and its 200 day simple moving average is $5.51.

Lipocine (NASDAQ:LPCN) last posted its quarterly earnings data on Monday, March 9th. The specialty pharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.26. Lipocine had a negative net margin of 487.00% and a negative return on equity of 59.30%. The firm had revenue of $1.15 million during the quarter, compared to the consensus estimate of $0.12 million.

Institutional Investors Weigh In On Lipocine

Large investors have recently bought and sold shares of the company. Citadel Advisors LLC bought a new position in Lipocine in the 3rd quarter valued at about $41,000. Geode Capital Management LLC raised its position in shares of Lipocine by 2.2% in the 4th quarter. Geode Capital Management LLC now owns 62,450 shares of the specialty pharmaceutical company’s stock valued at $502,000 after buying an additional 1,374 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Lipocine by 3.6% during the 4th quarter. Renaissance Technologies LLC now owns 37,397 shares of the specialty pharmaceutical company’s stock worth $300,000 after acquiring an additional 1,300 shares during the period. Jane Street Group LLC bought a new stake in shares of Lipocine during the 4th quarter worth approximately $85,000. Finally, Persistent Asset Partners Ltd acquired a new stake in shares of Lipocine during the 4th quarter worth approximately $567,000. 9.11% of the stock is currently owned by institutional investors and hedge funds.

About Lipocine

Lipocine Inc is a clinical-stage pharmaceutical company focused on the development and commercialization of oral drug delivery technologies. The company’s core expertise lies in lipid-based formulations designed to improve the bioavailability of therapeutics that traditionally require injectable administration. By leveraging proprietary technologies, Lipocine aims to offer patient-friendly alternatives with the potential for more consistent pharmacokinetic profiles and improved compliance.

The company’s lead product, TLANDO (LPCN 1021), is an oral testosterone replacement therapy approved by the U.S.